Skip to main content
. 2020 Sep 21;2(11):e689–e697. doi: 10.1016/S2665-9913(20)30305-2

Table 1.

Baseline variables independently associated with hydroxychloroquine selection by multivariate logistic regression

Odds ratio 95% CI p value
Rheumatoid arthritis 1·29 1·19–1·40 <0·0001
Systemic lupus erythematosus 4·13 3·79–4·51 <0·0001
Polyarthritis 1·21 1·03–1·42 0·021
Behcet's syndrome 0·26 0·07–0·67 0·0031
Connective tissue disease 3·58 3·11–4·10 <0·0001
Palindromic rheumatism 2·74 2·07–3·59 <0·0001
Polyarthralgia rheumatica 0·81 0·69–0·93 0·0038
Leflunomide 1·19 1·00–1·40 0·049
Sulfasalazine 2·00 1·71–2·29 <0·0001
Chronic steroids 1·80 1·65–1·96 <0·0001
Prednisone equivalent >20 mg per day 0·58 0·41–0·81 0·0011
Any other csDMARD* 2·12 1·78–2·53 <0·0001
Other csDMARD* plus biologic 0·78 0·66–0·92 0·0024
Methotrexate plus biologic 0·78 0·64–0·96 0·018
Vitamin D 1·48 1·40–1·56 <0·0001
Angiotensin II receptor blocker 1·43 1·32–1·55 <0·0001
Angiotensin-converting enzyme 2 inhibitor 1·48 1·38–1·57 <0·0001
Low haemoglobin 1·44 1·37–1·51 <0·0001
Elevated lactate dehydrogenase 1·37 1·22–1·55 <0·0001
Thrombocytopenia 1·12 1·02–1·24 0·021
Leucopenia 1·23 1·02–1·49 0·031
Elevated erythrocyte sedimentation rate 1·41 1·32–1·50 <0·0001

csDMARD=conventional synthetic disease-modifying antirheumatic drug.

*

csDMARDs include hydroxychloroquine, methotrexate, leflunomide, and sulfasalazine; other csDMARD refers to agents other than hydroxychloroquine.